Anxiety in Huntington's Disease
Anxiety in Huntington's Disease
复制标题
DOI：
10.1176/appi.neuropsych.14100265
复制
发表时间：
2015-09-01
影响因子：
2.9
通讯作者：
van Duijn, Erik
中科院分区：
文献类型：
--
作者：
Dale, Maria;van Duijn, Erik
焦虑在亨廷顿病(HD)中很常见，尽管对它的研究还不够深入。作者对HD患者的焦虑进行了系统的综述。显性HD患者焦虑发生率为13%~71%。显性和显性HD携带者在焦虑方面无显著差异。焦虑似乎与抑郁、自杀、易怒、生活质量、疼痛、疾病信念和应对方式有关，但似乎与疾病进展的衡量标准无关。从现有的为数不多的试点研究中，显示出希望的干预措施包括奥氮平和心理社会方法。需要改进评估，更多地探索HD中焦虑的性质，并对焦虑干预进行评估。
Anxiety is common in Huntington's disease (HD), though it has been under-researched. The authors conducted a systematic review of anxiety in HD. The prevalence of anxiety in manifest HD ranged from 13% to 71%. No significant difference in anxiety between manifest and premanifest HD carriers was revealed. Anxiety appears to be associated with depression, suicide, irritability, quality of life (QoL), pain, illness beliefs, and coping styles but does not seem to be linked with measures of disease progression. From the few pilot studies available, interventions that show promise include olanzapine and psychosocial approaches. Improved assessment, more exploration of the nature of anxiety in HD, and evaluation of anxiety interventions are required.